miércoles, 31 de agosto de 2011

Drug Safety and Availability > FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections

FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections

The U.S. Food and Drug Administration (FDA) is alerting health care professionals that repackaged intravitreal injections of Avastin (bevacizumab) have caused a cluster of serious eye infections in the Miami, Florida area.
The Florida Department of Health (DOH) notified FDA of a cluster of Streptococcus endophthalmitis infections in three clinics following intravitreal injection of repackaged Avastin.  Investigators traced the tainted injections to a single pharmacy located in Hollywood, Florida.   The pharmacy repackaged the Avastin from sterile injectable 100 mg/4 mL, single-use, preservative-free vials into individual 1 mL single-use syringes.
The pharmacy then distributed the Avastin to multiple eye clinics for use in treating patients.  To date, FDA is aware of at least twelve patients in at least three of these clinics who had eye infection. While all of these patients had visual deficits prior to their injections with Avastin, some of these patients lost all remaining vision in that eye due to the endophthalmitis.
The agency and Florida health officials continue to investigate the cause of the infection.  While the investigation is not yet complete, the common link for the infections is the pharmacy that repackaged the Avastin and the single lot of Avastin used in the re-packaging.
Health care professionals should be aware that repackaging sterile drugs without proper aseptic technique can compromise product sterility, potentially putting the patient at risk for microbial infections.  Health care professionals should ensure that drug products are obtained from appropriate, reliable sources and properly administered.
Avastin solution for intravenous infusion is approved for the treatment of various types of cancers.  Some physicians also prescribe Avastin off-label for the treatment of wet age-related macular degeneration, although Avastin is not currently approved for this indication.  Lucentis (ranibizumab injection) has been approved by the FDA for wet age-related macular degeneration.
Health care professionals and patients are encouraged to report any adverse events, side effects, or product quality problems related with the use of repackaged intravitreal injections of Avastin to the FDA’s MedWatch Safety Information and Adverse Event Reporting program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm1
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Drug Safety and Availability > FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections

Uterine stem cells used to treat diabetes in mice, August 30, 2011 News Release - National Institutes of Health (NIH)

Tuesday, August 30, 2011
Contact:
Robert Bock
Marianne Glass Miller
301-496-5133

Uterine stem cells used to treat diabetes in mice

NIH-funded researchers convert cells from uterine lining into insulin-producing cells

Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes.
The endometrium, or uterine lining, is a source of adult stem cells. Normally, these cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.
The study’s findings suggest the possibility that endometrial stem cells could be used to develop insulin-producing islet cells. These islet cells could then be used to advance the study of islet cells transplantation as a treatment for people with diabetes. If the transplantation of islet cells derived from endometrial cells is perfected, the study authors write that women with diabetes could provide their own endometrial tissue for such a transplant, sidestepping the chance of rejection posed by tissue from another person. Endometrial stem cells are readily available and can be collected easily during a simple outpatient procedure. Endometrial tissue could also be collected after hysterectomy, the surgical removal of the uterus.
“The study findings are encouraging,” said Louis V. DePaolo, Ph.D., chief of the Reproductive Sciences Branch at the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which funded the study. “Research to transplant insulin-producing cells into patients with diabetes could proceed at a much faster pace with a relatively accessible source of donor tissue.”
The study authors note that such a treatment would be more useful for people with Type 1 diabetes, in which no insulin is produced. The treatment would be less useful for Type 2 diabetes, in which insulin is usually produced, but in which cells have difficulty using the insulin that is available.
The findings appear in Molecular Therapy. The study was conducted by Xavier Santamaria, Efi E. Massasa, Yuzhe Feng, Erin Wolff and Hugh Taylor, M.D., all of Yale University, New Haven, Conn.
The study authors write that endometrial tissue samples could be warehoused in a tissue bank. A large number of samples would make it comparatively easy to find compatible tissue for transplant to women who no longer have a uterus and to men. According to the Centers for Disease Control and Prevention, roughly 600,000 hysterectomies are performed each year in the United States as treatment for a number of disorders and conditions.
In their study, the researchers bathed endometrial stem cells in cultures containing special nutrients and growth factors. Responding to these substances, the endometrial stem cells adopted the characteristics of beta cells, cells of the pancreas that produce insulin.
The incubation process took about three weeks. During this time, the endometrial stem cells took on the shape of beta cells and began making proteins typically made by beta cells. The researchers found that some of these cells also produced insulin.
After a meal, the body breaks food down into components like the sugar, glucose. Glucose then circulates in the blood. In response, beta cells release insulin, which allows the body’s cells to take in the circulating glucose. In their study, the researchers exposed the mature stem cells to glucose and found that, like typical beta cells, the cultured cells responded by producing insulin.
Next, the researchers injected the mature, insulin-making cells into the kidney capsule (membrane surrounding the kidney) of mice having a laboratory-induced form of diabetes. The mice had few working beta cells and very high levels of blood glucose. In mice that did not receive the stem cell therapy, blood sugar levels remained high. Additionally, the mice became lethargic and developed cataracts—both signs of untreated diabetes.
In contrast, mice receiving the cell therapy were active and did not develop cataracts. However, the treatment was not entirely effective, as the animals’ blood sugar remained higher than normal. Still, the animals continued to produce some insulin for six weeks, until the researchers ended the study.
“Verifying how long this treatment stays effective is one of our next research priorities,” said Dr. Taylor, the study’s senior author. “We also will investigate how changing the nutrient bath or increasing the dose of injected cells could make this treatment more effective.”
Dr. Taylor explained that culture and transplantation of endometrial stem cells might prove useful principally for Type 1 diabetes. In this form of the disorder, the immune system destroys the body’s own insulin-producing cells. As a result, insulin is not available to bring blood glucose levels under control. Although a diabetic woman’s immune system would be unlikely to reject islet cells developed from her own endometrial stem cells, it is still possible that her immune system would eventually target the new islet cells in the same way it targeted her original islet cells in the pancreas. For this reason, studies using endometrial stem cells to treat diabetes might first need to find ways to quell the immune attack against the islet cells.
Dr. Taylor added that endometrial stem cell therapy also might one day prove most useful for patients with Type 2 diabetes. In this form of diabetes, islet cells still produce insulin, but cells have trouble using insulin. In some patients with Type 2 diabetes, beta cells eventually die off. Dr. Taylor suggested that the stem cell approach might be helpful for patients at this later stage of the disease.
This study was conducted as part of the NICHD funded nationwide Specialized Cooperative Centers Program in Reproduction and Infertility Research.
In 2010, the researchers published a study which showed that endometrial stem cells could replace brain cells lost in mice having a laboratory-induced form of Parkinson’s disease.
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute’s Web site at http://www.nichd.nih.gov/.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

Uterine stem cells used to treat diabetes in mice, August 30, 2011 News Release - National Institutes of Health (NIH)

Gene replacement treats copper deficiency disorder in mice, August 30, 2011 News Release - National Institutes of Health (NIH)

Tuesday, August 30, 2011
Contact:
Robert Bock
Marianne Glass Miller
301-496-5133

Gene replacement treats copper deficiency disorder in mice

NIH study first step in possible treatment advance for rare, fatal childhood disease

Gene therapy plus an injection of copper dramatically improved survival in mice with a condition that mimics the often fatal childhood disorder Menkes disease, according to a study by researchers at the National Institutes of Health.
Menkes disease results from a poorly functioning copy of the gene ATP7A. Ordinarily, the gene helps the body process the trace metal copper. In Menkes disease, the gene malfunctions. As a result, copper is not available for proper development. Although the disorder affects the entire body, it is most pronounced in the brain, which requires relatively larger amounts of copper during development than other organs and tissues. Copper is used in the formation of red blood cells, and for keeping nervous system tissue, bones, and the immune system healthy.
The syndrome affects 1 out of 50,000 to 100,000 newborns each year, the vast majority of them boys, according to the study’s senior author, Stephen Kaler, M.D., head of the Unit on Human Copper Metabolism in the Molecular Medicine Program at the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The disorder varies in severity, depending on the degree to which the gene is disabled. Those with the most poorly functioning copy of the gene fare worst, often dying very early in life. Current treatment consists of daily copper injections until a child is 3 years old, Dr. Kaler explained.
Copper injections can be effective when Menkes disease is detected early and there is some ability to process copper, as in the case of an ATP7A gene with partial function. However, severe and advanced cases generally are not treatable. Most children with the disease die before they reach 3 years of age.
In their study, Dr. Kaler and his colleagues tested a treatment to add a normal copy of ATP7A to mice with a malfunctioning copy of the gene. Their results suggest that one day it might be possible to provide Menkes disease patients with a functioning ATP7A gene.
photo of Zoom in of ventricles in the brain
“Even with our best efforts to date, mortality from this disease remains high,” Dr. Kaler said. “These pre-clinical findings in a mouse model of the disease suggest that gene therapy may be a way to help those human infants with Menkes disease who are the most difficult to treat at present.”
The study’s first author was Anthony Donsante, Ph.D., also from the Unit on Human Copper Metabolism. Other authors included researchers at the NIH’s National Institute of Neurological Disorders and Stroke, the University of Minnesota Medical School in Duluth and the Armed Forces Institute of Pathology.
The study findings appear online in the journal Molecular Therapy.
The researchers conducted their study using a strain of mice with a largely disabled copy of ATP7A. In these mice, the ability to transport copper is severely disrupted. The animals do not respond to copper injections alone and typically die within two weeks of birth. Functional ATP7A genes were inserted into the animals’ brains via a harmless virus carrying the gene. Once injected, copies of the virus entered some of the cells in the animals’ brains. The ATP7A gene then began functioning inside these brain cells and increased the ability to process copper.
The researchers divided the mice into three groups. They injected copper alone into the first group of mice. They injected the ATP7A-containing virus alone into a separate group of mice. Mice in both of these groups tended to live two to three days longer than did untreated mice. However, none survived beyond three weeks, the age at which mice typically are weaned from their mothers.
In a third group of mice, the researchers first injected the ATP7A-containing virus and then, a day later, a dose of copper. On average, these mice survived three times longer than did the untreated mice. Nearly 90 percent survived to weaning. Ten months after they were born, more than 20 percent were still alive.
On closer examination, the researchers learned that copper levels were much higher in the brains of mice receiving the treatment of ATP7A plus copper than were copper levels in the brains of the untreated mice. In addition, the brains of the treated mice showed far less damage than those of untreated mice.
Dr. Kaler explained that the study’s success may have been due to the area of the brain where the ATP7A-carrying viruses were injected. The researchers injected the treatment inside the brain’s ventricles—fluid-filled cavities inside the brain. This fluid is referred to as cerebrospinal fluid, because it bathes the brain and spinal cord. Cerebrospinal fluid is manufactured by specialized cells inside the ventricles, the choroid plexus epithelial cells. When the researchers examined brain tissue from the mice, they found that the injected ATP7A gene had been incorporated into these cells.
“Throughout life, choroid plexus cells are replaced very infrequently, which suggests that the beneficial effect of this treatment could persist indefinitely,” Dr. Kaler explained.
Direct injections of the combined treatment into the brain ventricles were shown to be effective in mice. But direct injections into the brain carry a risk of swelling and infections. For patients with Menkes disease, it would be preferable to find other, less intrusive, ways to deliver the replacement gene. One potential strategy would be to deliver the treatment into the cerebrospinal fluid of the spinal cavity in the lower back, using a common injection procedure known as lumbar puncture.
NINDS (http://www.ninds.nih.gov/) is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease—a burden borne by every age group, by every segment of society, by people all over the world.
About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute’s Web site at http://www.nichd.nih.gov/.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

Gene replacement treats copper deficiency disorder in mice, August 30, 2011 News Release - National Institutes of Health (NIH)

NIMH · Autism Risk in Younger Siblings May be Higher Than Previously Thought

Science Update • August 23, 2011

Autism Risk in Younger Siblings May be Higher Than Previously Thought

young girls painting Source: iStock
Parents of a child with autism spectrum disorder (ASD) face about a 19 percent chance that subsequent children will also develop ASD, according to a study partially funded by NIMH. This estimate is much higher than previous reports but may also be more accurate due to the study's size and design, according to the researchers. Their study was published August 15, 2011, online ahead of print in the journal Pediatrics.

Background

A few previous studies have explored the recurrence rate of ASD, or the likelihood of later-born siblings of children with ASD to also develop ASD. However, few studies addressed factors likely to influence risk estimates, such as:
  • Stoppage—the tendency for families to choose not to have more children after one child is diagnosed with ASD. Such families would not be included in research on ASD recurrence.
  • Overreporting—an error that can occur when researchers rely solely on parent reports or health records, which have been shown to inflate estimates.
  • Ascertainment bias—an example is overselection, which can occur when parents with one child who has ASD pay very close attention to a later child's development. They may be more likely to take part in ASD recurrence studies than other parents.
Taking a different approach, Sally Ozonoff, Ph.D., of the University of California-Davis, and colleagues evaluated data on 664 infants who were tested at 12 sites across the United States and Canada. All sites were members of the Baby Siblings Research Consortium (BSRC), an international network supported by the U.S. advocacy group Autism Speaks. All BSRC members contribute data to a centralized database that allows infant-sibling researchers to pool data across many sites and answer questions that require very large and geographically diverse samples to address.
The average age of the infant participants at the start of the study was 8 months, an age when signs of ASD are not usually present; two-thirds of the total study population were enrolled before age 6 months. All had at least one older sibling diagnosed with ASD, which was confirmed by a consortium doctor. The participants were themselves assessed for ASD multiple times in their first three years of life.

Results of the Study

Out of the total study sample, 18.7 percent of participants were diagnosed with ASD by age 3. Boys were nearly three times as likely as girls to be diagnosed with ASD. Participants who had more than one older sibling with ASD were about twice as likely to also be diagnosed with ASD, compared to participants who had only one older sibling with ASD.
Unlike some previous studies, the gender or IQ of the older sibling with ASD did not affect the later sibling's risk in the present study.

Significance

The findings indicate that ASD recurrence is 18 percent or higher, compared to 3-14 percent estimated in earlier studies. The researchers note that their study's size and design minimized the effects of stoppage, overreporting, and ascertainment bias.
Despite the strengths of their study, the researchers emphasize that recurrence estimates cannot provide information on an individual's risk. They highlight the need for careful and extensive counseling and thorough genetic work-ups for concerned parents, as well as close monitoring, especially of high-risk children, and prompt referrals for intervention by primary care providers.

What’s Next

According to the researchers, larger, population-based studies that include families of children with ASD who are not listed in the Baby Siblings Research Consortium may help to further refine recurrence estimates. Future studies will examine DNA collected from participants to examine genetic factors that may be associated with recurrence.

Reference

Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, Bryson S, Carver LJ, Constantino JN, Dobkins K, Hutman T, Iverson JM, Landa R, Rogers SJ, Sigman M, Stone WL. Recurrence Risk for Autism Spectrum Disorders: A Baby Siblings Research Consortium Study. Pediatrics. 2011 Aug 15. [Epub ahead of print] PubMed PMID: 21844053.
NIMH · Autism Risk in Younger Siblings May be Higher Than Previously Thought

NIMH · Suicide Prevention and Research

August 22, 2011

Suicide Prevention and Research

NIMH researcher Dr. Jane Pearson talks about warning signs as well as progress in suicide prevention.

Get Adobe Flash player


Download this video. Watch on YouTube.

Transcript

Dr. Jane Pearson: Suicide is a major public health problem in this country. And like other external causes of death — accidents, homicides — suicides are also considered external causes of death. And because of that, we think we have opportunities to prevent it.
Announcer: Dr. Jane Pearson is a leader of the suicide prevention research team at the National Institute of Mental Health in Bethesda. The tragedy of suicide touches large numbers of American families every year. But people across the globe now benefit from advances in suicide prevention research and guidelines that emerged from national and global strategies formed a decade ago. An example of specific action steps that have been developed can be found in medical emergency rooms.
Dr. Jane Pearson: We can do better for people who actually come to the emergency department saying they’re suicidal. We felt like we could find better ways of helping those people how to better screen, access them, treat them. I think some other areas we’ve made significant progress is in understanding what treatments seem to work at least for people who have attempted suicide. We’ve got some interventions, some psycho-social counseling for psychotherapy that look particularly effective. And a number of these use cognitive behavioral approaches that directly address people’s thinking about suicide. It’s really important in suicide prevention that we think of continuity of care when people’s care changes as they leave the hospital going back into the community. We know that’s a very high risk time. So we need to think about what would provide more continuous care — more support for both the individual and maybe their family members to help them stay well and to start getting the treatment that they need.
Announcer: An alliance of people and organizations, including researchers at NIMH, has uncovered critical pieces of information that include those individuals who may be at higher risk for suicide. Included are people with known mental disorders such as schizophrenia or bipolar. People with alcohol or drug problems may have higher risks along with those who suffer from chronic illness. A family history of suicide could serve as a warning as well as people who have been physically abused or neglected….
Dr. Jane Pearson: The highest risk groups are people — are older men, white men in particular who are 85 and older who have a rate of suicide that’s four times the national average. American Indian and Alaskan native males also have very high risks.
Announcer: There are many things we as individuals can do to look for warning signs but perhaps the best advice for loved ones and friends — don’t dismiss or minimize threats of suicide.
Dr. Jane Pearson: If somebody’s talking about suicide you really should take it seriously. There may be parents or even providers who say — oh, somebody just wants to get some attention. Well, they probably need to get some attention for a reason. It’s worth following through. It might be that we don’t know for sure if somebody really intends to or not. And the individual might not be certain either, but we certainly want to give them some help.
Announcer: Dr. Pearson’s work and wide-ranging NIMH-funded research have helped shed new light on suicide treatment and prevention.
Dr. Jane Pearson: We’re trying to pull together what we can learn from surveillance data to find the highest risk groups and really get them the interventions they need. And there are people across NIMH helping with this, across federal agencies. And I think there’s a lot of momentum, and I think we’ve got some good reason to hope that we can actually change these numbers.
NIMH · Suicide Prevention and Research

CDC - Key Data & Statistics in Injury & Violence Prevention - Injury

Injuries and Violence are Leading Causes of Death: Key Data & Statistics

Photo: Male teen basketball players talking to their coach
For Americans ages 1-44, injuries are the leading cause of death in the United States.
In the United States, injuries are the leading cause of death for people ages 1-44.1

The Burden

The consequences of injury are considerable and costly to public health:
  • In 2007, 182,479 persons died from injuries.1
  • In 2007, 2,855,000 persons were hospitalized for an injury.2
  • That same year, 29,757,000 persons were treated for nonfatal injuries in U.S. hospital emergency departments.1
In 2005, injuries accounted for an estimated $406 billion in medical and work loss costs, including deaths, hospitalizations, and ED visits where the patient was treated and released.3
This pie chart illustrates the percent cost of injury by mechanism (cause):

Data points for total cost of injury by mechanism pie chart: Twenty-four percent of injuries were due to other causes. Twenty-two percent of injuries were caused by motor vehicle/other road users. Falls accounted for 24 percent of all injuries. Struck by/against injuries accounted for 12 percent of all injuries.  Nine percent of injuries were caused by firearms/gunshots. Poisoning accounted for six percent of all injuries. Four percent of all injuries were due to cut/pierce injuries. Two percent of injuries were caused by fires and burns. Drowning/submersion accounted for one percent of all injuries.

The Impact on America’s Youth and Young Adults

Photo: Teenagers standing around a car
For those age 5-34 in the United States, motor vehicle crashes are the leading cause of death.
Injuries and violence affect us all, but three quarters of all deaths among young people are the result of injuries and violence. 
  • Among persons aged 1–34 years, unintentional injuries alone claim more lives than any other cause.1
  • For those aged 5–34 in the United States, motor vehicle crashes are the leading cause of death, claiming the lives of 18,266 Americans each year.1
  • For 15–24 year olds, homicide is the second leading cause of death and claims more than 8,500 lives each year; suicide is the third leading cause of death among this group and claims 4,140 lives each year.1 
  • For 25–34 year olds, suicide is the second leading cause of death, and homicide is the third leading cause of death.1
While injuries and violence cause death and disability, it is possible to prevent them.  For more information about injuries and CDC’s response, visit the following sites:
  • WISQARS™ (Web-based Injury Statistics Query and Reporting System) WISQARS™ is an interactive, online database that provides fatal and nonfatal injury, violent death, and cost of injury data from a variety of trusted sources.
  • Burden of Injury & Violence: A Pressing Public Health Concern Injuries and violence are widespread in society. Many people accept them as fate or as “part of life,” but the fact is that most events resulting in injury, death or disability are predictable and therefore preventable. The burden of injuries and violence coupled with the enormous cost of these problems to society make them a pressing public health concern.

References

  1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS) [online] (2007) [cited 2011 Mar 4]. Available from URL: http://www.cdc.gov/injury/wisqars.
  2. Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS). National hospital discharge survey: 2007 summary. National health statistics reports, no. 29. Atlanta, GA: NCHS; 2010.
  3. Finkelstein EA, Corso PS, Miller TR, Associates. Incidence and economic burden of injuries in the United States. New York, NY: Oxford University Press; 2006.
CDC - Key Data & Statistics in Injury & Violence Prevention - Injury

Toddler's Dust Mite Sensitivity May Predict Later Asthma: MedlinePlus

Toddler's Dust Mite Sensitivity May Predict Later Asthma

Three-quarters who tested positive at 2 years had respiratory problem at age 12, study finds
(*this news item will not be available after 11/27/2011)

By Robert Preidt
Monday, August 29, 2011 HealthDay Logo
HealthDay news image
Related MedlinePlus Pages
MONDAY, Aug. 29 (HealthDay News) -- Toddlers with a sensitivity to house dust mites have an increased risk of developing asthma by the time they're 12, new research suggests.
The study included 620 Australian children with a family history of allergies who were followed from birth to age 12. The children were given a skin prick test at ages 6 months and 1 and 2 years to check for sensitivity to different allergens and then tested at age 12 for asthma.
Asthma was diagnosed in 75 percent of the children who tested positive for sensitivity to house dust mites when they were infants, compared with 36 percent of those who didn't have a sensitivity to dust mites.
"Our study did not show house dust mite caused asthma but it highlighted a strong correlation between sensitivity and more severe wheeze and asthma," lead author Dr. Caroline Lodge, of the School of Population Health at the University of Melbourne, said in a university news release.
Identifying groups of high-risk children may help researchers learn more about asthma development and find ways to prevent it, she said.
The study was published online this month in the Journal of Allergy and Clinical Immunology.
SOURCE: University of Melbourne, news release, Aug. 24, 2011
HealthDay

More Health News on:
Allergy
Asthma in Children
Recent Health News
Related MedlinePlus Pages
Page last updated on 30 August 2011
Toddler's Dust Mite Sensitivity May Predict Later Asthma: MedlinePlus